Literature DB >> 29554462

Structure, Function, and Applications of the Georgetown-Einstein (GE) Breast Cancer Simulation Model.

Clyde B Schechter1, Aimee M Near2, Jinani Jayasekera2, Young Chandler2, Jeanne S Mandelblatt2.   

Abstract

BACKGROUND: The Georgetown University-Albert Einstein College of Medicine breast cancer simulation model (Model GE) has evolved over time in structure and function to reflect advances in knowledge about breast cancer, improvements in early detection and treatment technology, and progress in computing resources. This article describes the model and provides examples of model applications.
METHODS: The model is a discrete events microsimulation of single-life histories of women from multiple birth cohorts. Events are simulated in the absence of screening and treatment, and interventions are then applied to assess their impact on population breast cancer trends. The model accommodates differences in natural history associated with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) biomarkers, as well as conventional breast cancer risk factors. The approach for simulating breast cancer natural history is phenomenological, relying on dates, stage, and age of clinical and screen detection for a tumor molecular subtype without explicitly modeling tumor growth. The inputs to the model are regularly updated to reflect current practice. Numerous technical modifications, including the use of object-oriented programming (C++), and more efficient algorithms, along with hardware advances, have increased program efficiency permitting simulations of large samples.
RESULTS: The model results consistently match key temporal trends in US breast cancer incidence and mortality.
CONCLUSION: The model has been used in collaboration with other CISNET models to assess cancer control policies and will be applied to evaluate clinical trial design, recurrence risk, and polygenic risk-based screening.

Entities:  

Keywords:  breast cancer; simulation modeling

Mesh:

Substances:

Year:  2018        PMID: 29554462      PMCID: PMC5862062          DOI: 10.1177/0272989X17698685

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  23 in total

1.  How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach.

Authors:  E J Feuer; L M Wun
Journal:  Am J Epidemiol       Date:  1992-12-15       Impact factor: 4.897

2.  Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Authors:  Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

3.  Estimation of the duration of a pre-clinical disease state using screening data.

Authors:  S D Walter; N E Day
Journal:  Am J Epidemiol       Date:  1983-12       Impact factor: 4.897

4.  Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States.

Authors:  Nicolien T van Ravesteyn; Clyde B Schechter; Aimee M Near; Eveline A M Heijnsdijk; Michael A Stoto; Gerrit Draisma; Harry J de Koning; Jeanne S Mandelblatt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-11-30       Impact factor: 4.254

5.  Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.

Authors:  Nicolien T van Ravesteyn; Diana L Miglioretti; Natasha K Stout; Sandra J Lee; Clyde B Schechter; Diana S M Buist; Hui Huang; Eveline A M Heijnsdijk; Amy Trentham-Dietz; Oguzhan Alagoz; Aimee M Near; Karla Kerlikowske; Heidi D Nelson; Jeanne S Mandelblatt; Harry J de Koning
Journal:  Ann Intern Med       Date:  2012-05-01       Impact factor: 25.391

6.  Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.

Authors:  Brian L Sprague; Natasha K Stout; Clyde Schechter; Nicolien T van Ravesteyn; Mucahit Cevik; Oguzhan Alagoz; Christoph I Lee; Jeroen J van den Broek; Diana L Miglioretti; Jeanne S Mandelblatt; Harry J de Koning; Karla Kerlikowske; Constance D Lehman; Anna N A Tosteson
Journal:  Ann Intern Med       Date:  2015-02-03       Impact factor: 25.391

7.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

8.  Benefits and costs of interventions to improve breast cancer outcomes in African American women.

Authors:  Jeanne S Mandelblatt; Clyde B Schechter; K Robin Yabroff; William Lawrence; James Dignam; Peter Muennig; Yoko Chavez; Jennifer Cullen; Marianne Fahs
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

9.  Using Simulation Modeling to Inform Strategies to Reduce Breast Cancer Mortality in Black Women in the District of Columbia.

Authors:  Aimee M Near; Jeanne S Mandelblatt; Clyde B Schechter; Michael A Stoto
Journal:  Epidemiol Res Int       Date:  2012-04-26

10.  Toward optimal screening strategies for older women. Costs, benefits, and harms of breast cancer screening by age, biology, and health status.

Authors:  Jeanne S Mandelblatt; Clyde B Schechter; K Robin Yabroff; William Lawrence; James Dignam; Martine Extermann; Sarah Fox; Gretchen Orosz; Rebecca Silliman; Jennifer Cullen; Lodovico Balducci
Journal:  J Gen Intern Med       Date:  2005-06       Impact factor: 5.128

View more
  15 in total

1.  Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Authors:  Sylvia K Plevritis; Diego Munoz; Allison W Kurian; Natasha K Stout; Oguzhan Alagoz; Aimee M Near; Sandra J Lee; Jeroen J van den Broek; Xuelin Huang; Clyde B Schechter; Brian L Sprague; Juhee Song; Harry J de Koning; Amy Trentham-Dietz; Nicolien T van Ravesteyn; Ronald Gangnon; Young Chandler; Yisheng Li; Cong Xu; Mehmet Ali Ergun; Hui Huang; Donald A Berry; Jeanne S Mandelblatt
Journal:  JAMA       Date:  2018-01-09       Impact factor: 56.272

2.  Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.

Authors:  Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

3.  Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort.

Authors:  Marc D Ryser; Jane Lange; Lurdes Y T Inoue; Ellen S O'Meara; Charlotte Gard; Diana L Miglioretti; Jean-Luc Bulliard; Andrew F Brouwer; E Shelley Hwang; Ruth B Etzioni
Journal:  Ann Intern Med       Date:  2022-03-01       Impact factor: 51.598

4.  Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Authors:  Oguzhan Alagoz; Donald A Berry; Harry J de Koning; Eric J Feuer; Sandra J Lee; Sylvia K Plevritis; Clyde B Schechter; Natasha K Stout; Amy Trentham-Dietz; Jeanne S Mandelblatt
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

5.  Common Model Inputs Used in CISNET Collaborative Breast Cancer Modeling.

Authors:  Jeanne S Mandelblatt; Aimee M Near; Diana L Miglioretti; Diego Munoz; Brian L Sprague; Amy Trentham-Dietz; Ronald Gangnon; Allison W Kurian; Harald Weedon-Fekjaer; Kathleen A Cronin; Sylvia K Plevritis
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

6.  Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

Authors:  Nicolien T van Ravesteyn; Jeroen J van den Broek; Xiaoxue Li; Harald Weedon-Fekjær; Clyde B Schechter; Oguzhan Alagoz; Xuelin Huang; Donald L Weaver; Elizabeth S Burnside; Rinaa S Punglia; Harry J de Koning; Sandra J Lee
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

7.  Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.

Authors:  Jeroen J van den Broek; Nicolien T van Ravesteyn; Jeanne S Mandelblatt; Mucahit Cevik; Clyde B Schechter; Sandra J Lee; Hui Huang; Yisheng Li; Diego F Munoz; Sylvia K Plevritis; Harry J de Koning; Natasha K Stout; Marjolein van Ballegooijen
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

8.  Long-Term Outcomes and Cost-Effectiveness of Breast Cancer Screening With Digital Breast Tomosynthesis in the United States.

Authors:  Kathryn P Lowry; Amy Trentham-Dietz; Clyde B Schechter; Oguzhan Alagoz; William E Barlow; Elizabeth S Burnside; Emily F Conant; John M Hampton; Hui Huang; Karla Kerlikowske; Sandra J Lee; Diana L Miglioretti; Brian L Sprague; Anna N A Tosteson; Martin J Yaffe; Natasha K Stout
Journal:  J Natl Cancer Inst       Date:  2020-06-01       Impact factor: 13.506

9.  Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness.

Authors:  Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Grace O'Brien; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Melissa M Hudson; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Paul C Nathan; Joseph P Neglia; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout
Journal:  J Natl Cancer Inst       Date:  2022-02-07       Impact factor: 11.816

10.  Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer.

Authors:  Jinani Jayasekera; Joseph A Sparano; Robert Gray; Claudine Isaacs; Allison Kurian; Suzanne O'Neill; Clyde B Schechter; Jeanne Mandelblatt
Journal:  JNCI Cancer Spectr       Date:  2019-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.